M1FG
BCRX icon

Mach-1 Financial Group’s BioCryst Pharmaceuticals BCRX Stock Holding History

Mach-1 Financial Group’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-36,660
Closed -$328K – 266
2025
Q2 		$328K Sell
36,660
-1,699
-4% -$15.8K 0.1% 182
2025
Q1 		$288K Buy
+38,359
New +$309K 0.09% 210

Other funds holding BCRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Mach-1 Financial Group's BCRX Position: Q3 2025 in Review

Mach-1 Financial Group sold out of BioCryst Pharmaceuticals (BCRX) in Q3 2025, closing a stake of 36,660 shares — an estimated $328K sold.

Mach-1 Financial Group first reported a position in BCRX in Q1 2025 and held it in 2 quarters. The position peaked at $328K in Q2 2025. 286 funds tracked by Wall St. Rank hold BCRX as of Q3 2025.

  • Mach-1 Financial Group reported no remaining BioCryst Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Mach-1 Financial Group sold 36,660 BioCryst Pharmaceuticals shares in Q3 2025, an estimated $328K.
  • Mach-1 Financial Group first reported a position in BioCryst Pharmaceuticals in Q1 2025 and held it in 2 quarters.
  • Mach-1 Financial Group's BioCryst Pharmaceuticals position peaked at $328K in Q2 2025.
  • 286 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q3 2025.

Based on Mach-1 Financial Group's 13F filing for Q3 2025, filed 12 Nov 2025.